



## Presentations at BIO KOREA 2021

### Cocoon® Platform – the next level in patient-specific cell therapy manufacturing

Discover the next level in closed and automated cell processing. The Cocoon® Platform streamlines patient-scale cell therapy manufacturing for greater efficiency and reliability. Automated, closed and flexible, this end-to-end cell manufacturing platform gives you increased control over your specific process.

Highly customizable and scalable, the Cocoon® Platform is an integrated turnkey solution ready to use off-the-shelf. If you want full customization, we'll work with you to tailor it to your unique process. Designed to save time and lower costs, Cocoon® enables you to quickly and efficiently advance your project from pre-clinical through commercial-scale manufacturing. Whether manufacturing in a centralized or decentralized model, our approach to cell therapy manufacturing with the Cocoon® Platform reduces costs and risk, while improving overall product quality.

Dr. Nicholas Ostrout will be sharing about Cocoon® Platform.

[Date & Time: 10 June 2021, 11:30- 12:00 \(Room 317\)](#)



The Cocoon® Platform: What you should expect for true scalability from a closed and automated cell therapy manufacturing system

Nicholas Ostrout

Head of Commercial and Business Development Personalized Medicine – Lonza, Personalized Medicine, Lonza Pharma & Biotech

### Background of Dr. Nicholas Ostrout

Dr. Nicholas Ostrout leads the commercial development team for Personalized Medicine. Dr. Ostrout earned his PhD in Immunology from Case Western Reserve University and has been working in sales, marketing, and business development for most of his career. Nicholas most recently came from Miltenyi Biosciences. Dr. Ostrout is primarily focused on launching the Cocoon Platform into the market and scaling out manufacturing capabilities for cell and gene therapies with the Cocoon both internally within Lonza and with external partners. Nick's primary goal, as part of Lonza's PerMed team, is to make these lifesaving cell therapies at a lower cost, and on a higher scale, in order to be able to treat as many patients as possible.

**Mr. Alberto Santagostino will be discussing how to industrialize and bring Cell and Gene Therapies to the masses.**

**Date & Time: 11 June 2021, 13:00 – 13:30 (Room 308)**



**Leveraging “The cubic Effect” for the necessary industrialization of Cell and Gene Therapy manufacturing processes**

**Alberto Santagostino**

Head of the Cell and Gene Technologies Business Unit at Lonza Pharma & Biotech

### Background of Alberto Santagostino

Together with his team, Alberto's objective is to serve customers by taking their products through the technical CMC journey to commercialization and industrial scale manufacturing.

Before joining Lonza Pharma & Biotech, Alberto was a Partner at McKinsey & Company, accruing 12 years of experience working closely with established industry leaders and emerging players. Alberto led the Biotechnology service line, as well as the Pharmaceutical and Medical Product practice, and has a deep knowledge of the manufacturing challenges faced by companies in the biopharma space.

Alberto is passionate about biotechnology- the science and the business.

**To attend these presentations, please register for a session at BioKorea (Registration fee required)**

<https://www.biokorea.org/registration/program.asp>

We look forward to welcoming you.

[Home](#) | [Contact Us](#) | [Unsubscribe](#)



© 2021 Lonza. All trademarks belong to Lonza or its affiliates.

The information contained herein is believed to be correct. No warranty is made, either expressed or implied.

For further information on how we collect, use and process personal information and your rights in connection therewith, please visit [lonza.com/privacy](https://lonza.com/privacy).